OTCM
VICA
Market cap14kUSD
Jul 09, Last price
0.00USD
Jan 2017
-99.89%
IPO
-99.90%
Name
Omed Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
61.68%
Revenues
3m
Net income
-879k
L+934.63%
CFO
-2m
L+299.60%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rafina Innovations Inc. is a company that develops, researches, commercializes, and markets medical technologies. Its operations are divided into two main areas: its Clinic division and its Technology division. The company manages specialized rehabilitation clinics for prosthetics, orthotics, and comprehensive diabetic foot care, serving patients in Southern Europe, the Middle East, and North Africa. Within its Technology arm, Rafina Innovations Inc. is actively engaged in the creation, development, and market introduction of medical devices, innovative methods, and products. This work covers a broad range of fields, including but not limited to, prosthetics, orthotics, general rehabilitation, bioengineering, mobility, diabetes and diabetic foot care, tissue mechanics, ultrasonics, medical signal processing and analysis, general medical technology, orthopedics, and robotic surgery. Additionally, the company licenses its proprietary technological advancements. Founded in 2007, the company changed its name from HCi Viocare to Rafina Innovations Inc. in July 2018. Its base of operations is in Glasgow, United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||